The epidemic caused by the SARS-CoV-2 virus reached Poland in early March 2020. Taking into account its development, the measures taken to limit the spread of the virus and the effects of COVID-19, as well as the very awareness of the threat among the public, Anna Rulkiewicz, CEO of the LUX MED Group, in an…
Aviva, a company operating on the insurance market and offering, among others, health insurance, wants to sell its assets in Poland, according to unofficial information provided by Bloomberg. The price of such a transaction could reach even €1.5bn. Aviva will leave Poland? Aviva, a company operating on the insurance market, is looking to sell its…
Recently, more is happening on the market for acquisitions among medical companies. That is why we decided to take a closer look at this topic. Wojciech Lukawski and Sylwester Urbanek from Abris Capital Partners talk about whether the pandemic has influenced investments in the medical industry. The interview with PMR also includes information about the…
Since December, Robert Lasota has been Corporate Sales Department Director at Signal Iduna. One of his goals is to coordinate the development of corporate health insurance. Rich experience and ambitious goals at Signal Iduna Lasota has been associated with the insurance industry for nearly 26 years. He started working in the field of insurance in…
In 2019 the imaging diagnostic services market value was over PLN 6.2bn. This represented an increase of almost 11% year on year, according to PMR’s latest report entitled “Diagnostic imaging and radiotherapy market in Poland 2020. Market analysis and development forecasts for 2020-2025”. Changes in external conditions significantly affect the imaging diagnostic market In the…
Yesterday Generali Polska informed that Julita Czyzewska will join the company team. The former president of PZU Zdrowie in her new position will be responsible for the development of the health area. Is competition on the private health insurance market growing? Valuable experience for Generali Czyzewska is an economist by education. She has a diploma…
Polish start-up HomeDoctor intends to develop services offered through its portal. This is mainly about teleconsultations and home visits. Cogito Capital Partners fund has recently invested in the company. EUR 3.7m for HomeDoctor HomeDoctor has announced a round of financing for Series A worth EUR 3.7m, to be conducted by Cogito Capital Partners and the…
This year’s industry event: I Private Healthcare Forum in Poland is behind us! On 10 September 2020, we met among key providers, manufacturers of medical equipment, IT solutions, pharmaceutical companies as well as investors and media partners to discuss the situation in the sector and forecasts for the next year. The event was full of…
The development speed of the private healthcare market largely depends on the condition of the Polish economy, in particular the situation of enterprises, as well as families, who are consumers in the FFS segment. As Anna Janiczek, CEO of PZU Zdrowie, says in an interview with PMR, current forecasts for the development of the private…
According to Gilead Sciences, the coronavirus drug costs nearly $400. Remdesivir reduces recovery time from COVID-19 by four days. Effectiveness of remdesivir in the treatment of COVID-19 Remdesivir was developed by the American company Gilead Sciences as an antiviral drug to treat Ebola. However, used for this purpose, it did not show the expected efficacy….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.